To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.

Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Arms Length Body Publication (Published)
NICE

Oct. 22 2025

Source Page: VA ECMO for severe acute heart failure in adults
Publication Type: Supporting evidence
Document: Overview final (PDF 994 KB) (webpage)
Arms Length Body Publication (Published)
NICE

Oct. 22 2025

Source Page: VA ECMO for severe acute heart failure in adults
Publication Type: Summary PDF
Document: Download guidance (PDF) (webpage)
Arms Length Body Publication (Published)
NICE

Oct. 22 2025

Source Page: VA ECMO for severe acute heart failure in adults
Publication Type: Guidance published
Document: Consultation comments and responses (PDF 234 KB) (webpage)
Arms Length Body Publication (Published)
NICE

Oct. 22 2025

Source Page: VA ECMO for severe acute heart failure in adults
Publication Type: Guidance published
Document: Equality impact assessment (downloadable version) (PDF 147 KB) (webpage)
Arms Length Body Publication (Published)
NICE

Oct. 22 2025

Source Page: VA ECMO for severe acute heart failure in adults
Publication Type: Summary PDF
Document: Download (PDF) (webpage)
Arms Length Body Publication (Published)
NICE

Oct. 22 2025

Source Page: VA ECMO for severe acute heart failure in adults
Publication Type: Clinical classification
Document: Clinical classification codes (PDF 58 KB) (webpage)
Arms Length Body Publication (Published)
NICE

Oct. 21 2025

Source Page: Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor
Publication Type: Expected publication
Document: TA909 FDG Committee papers (PDF 1.19 MB) (webpage)
Arms Length Body Publication (Published)
NICE

Oct. 21 2025

Source Page: Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor
Publication Type: Expected publication
Document: TA909 FDG Committee papers (PDF 1.19 MB) (webpage)
Arms Length Body Publication (Published)
NICE

Oct. 21 2025

Source Page: Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor
Publication Type: Expected publication
Document: TA909 Final Draft Guidance (PDF 416 KB) (webpage)
Arms Length Body Publication (Published)
NICE

Oct. 21 2025

Source Page: Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor
Publication Type: Expected publication
Document: TA 909 Final scope (PDF 169 KB) (webpage)